AIRLINK 152.10 Decreased By ▼ -3.61 (-2.32%)
BOP 10.05 Decreased By ▼ -0.26 (-2.52%)
CNERGY 7.28 Decreased By ▼ -0.37 (-4.84%)
CPHL 85.00 Decreased By ▼ -3.17 (-3.6%)
FCCL 46.55 Decreased By ▼ -0.81 (-1.71%)
FFL 15.77 Decreased By ▼ -0.35 (-2.17%)
FLYNG 54.69 Decreased By ▼ -3.32 (-5.72%)
HUBC 136.60 Decreased By ▼ -1.92 (-1.39%)
HUMNL 11.30 Decreased By ▼ -0.24 (-2.08%)
KEL 5.33 Decreased By ▼ -0.14 (-2.56%)
KOSM 5.63 Increased By ▲ 0.17 (3.11%)
MLCF 82.49 Decreased By ▼ -1.26 (-1.5%)
OGDC 208.88 Decreased By ▼ -3.17 (-1.49%)
PACE 6.03 Increased By ▲ 0.17 (2.9%)
PAEL 41.43 Decreased By ▼ -1.79 (-4.14%)
PIAHCLA 22.52 Increased By ▲ 0.76 (3.49%)
PIBTL 8.12 Decreased By ▼ -0.30 (-3.56%)
POWER 13.79 Decreased By ▼ -0.57 (-3.97%)
PPL 166.66 Decreased By ▼ -4.33 (-2.53%)
PRL 32.16 Decreased By ▼ -1.33 (-3.97%)
PTC 24.40 Decreased By ▼ -1.10 (-4.31%)
SEARL 89.45 Decreased By ▼ -3.44 (-3.7%)
SSGC 41.40 Decreased By ▼ -0.52 (-1.24%)
SYM 14.84 Decreased By ▼ -0.16 (-1.07%)
TELE 7.70 Decreased By ▼ -0.12 (-1.53%)
TPLP 9.11 Decreased By ▼ -0.20 (-2.15%)
TRG 63.29 Decreased By ▼ -0.93 (-1.45%)
WAVESAPP 9.12 Decreased By ▼ -0.30 (-3.18%)
WTL 1.45 Increased By ▲ 0.08 (5.84%)
YOUW 4.15 Decreased By ▼ -0.04 (-0.95%)
BR100 13,055 Decreased By -190.1 (-1.43%)
BR30 37,792 Decreased By -679.1 (-1.77%)
KSE100 122,144 Decreased By -1949.6 (-1.57%)
KSE30 36,883 Decreased By -653.4 (-1.74%)

Pfizer Inc and partner BioNTech have completed the filing with the US drugs regulator seeking authorization for their COVID-19 vaccine in children under 5 years of age.

The filing with the US Food and Drug Administration (FDA), completed on Wednesday, included data showing three lower-dose shots of the vaccine generated a strong immune response in children as young as 6 months of age.

No COVID-19 shot is yet approved for children in that age group in most parts of the world. It remains unclear how many parents will get their young ones vaccinated as demand has been low in kids aged 5 to 11.

US doctors reconsider Pfizer’s Paxlovid for lower-risk COVID patients

Pfizer and BioNTech on May 23 said their trial showed a 3 microgram version of the vaccine generated a similar immune response in under 5-year-olds as two doses of 30 micrograms each in 16 to 25-year-olds in an earlier trial.

Rival Moderna in March released trial data that showed a two-dose formulation of its vaccine was safe and generated a similar immune response in young children as in adults.

The FDA’s independent advisers will discuss the two applications in a meeting set for June 15.

Comments

Comments are closed.